Longboard Pharmaceuticals Announces Positive Interim Results From the Open-Label Extension (Ole) of the Phase 1B/2a Pacific Study Evaluating Bexicaserin in Participants With Developmental and Epileptic Encephalopathies (Dees)
Longboard藥品宣佈，評估Bexicaserin用於發育性和癲癇性腦病的參與者的1B/2a太平洋研究的開放標籤延期（Ole）取得了積極的中期結果。